Sodium 2-Hydroxylinoleate

3 trials 1 recruiting Orphan designation

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

2 Sponsors

2 Countries

Phase I/II

Phase I/II: 3

Sponsors using this IMP

Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron 2 Ability Pharmaceuticals S.A. 1

All trials

3 total

A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours Not authorised

2023-504246-64-00 Phase I/II 1 country Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron
A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours Recruiting

2023-504246-64-02 Phase I/II 1 country Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron
A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with F… Ended

2024-515379-36-00 Phase I/II 2 countries Ability Pharmaceuticals S.A.

Showing 1–3 of 3 trials

← All drugs A–Z